Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 2/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558333 | 0.75 | FFAR1 (0.32) | GAAL3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL1856006 | 0.75 | MAPK1 (0.38) | GAAHPGDTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL558395 | 0.75 | NOS1 (0.42) | GAAKDM4EMAPTKMT2APSMB8 | |
| SCHEMBL7258404 | 0.71 | GABRA1 (0.38) | KDM4EPOLBMAPTMEN1KMT2A | |
| SCHEMBL558190 | 0.71 | AXL (0.47) | KDM4EAXLHSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL8773802 | 0.69 | KDM4E (0.37) | GAACYP3A4PDPK1KDM4ETDP1 | |
| SCHEMBL647458 | 0.68 | NOS1 (0.50) | GAACYP3A4KDM4ETDP1POLB | |
| SCHEMBL3079936 | 0.67 | BCHE (0.40) | GAACYP3A4KDM4ETDP1MAPT | |
| SCHEMBL6784301 | 0.66 | — | — | |
| SCHEMBL2557 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4712702-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | claimed |
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-28 | — | — | US | claimed |
| EP-1651652-B1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1651652-A1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005010008-A1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| US-10173985-B2 | Aminoindazole derivatives as sodium channel inhibitors | ALMIRALL, S.A. (ES) | 2019-01-08 | — | — | US | disclosed |
| US-10173985-B2 | Aminoindazole derivatives as sodium channel inhibitors | ALMIRALL, S.A. (ES) | 2019-01-08 | — | — | US | disclosed |
| US-10112936-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180244626-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-08-30 | — | — | US | disclosed |
| US-20180244626-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-08-30 | — | — | US | disclosed |
| US-20180105509-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-04-19 | — | — | US | disclosed |
| EP-3286178-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | Almirall S.A. (ES) | 2018-02-28 | — | — | EP | disclosed |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-22 | — | — | US | disclosed |
| WO-2005010008-A1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20030175935-A1 | Method of identifying inhibitors of Lck | ABBVIE INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003020880-A2 | METHOD OF IDENTIFYING INHIBITORS OF LCK | ABBOTT LABORATORIES (US) | 2003-03-13 | — | — | WO | disclosed |
| US-6452000-B2 | ALKYLATION; ACYLATION; CYCLIZATION; IMINATION; USEFUL AS HIV PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-17 | — | — | US | disclosed |
| US-20010020093-A1 | Preparation of asymmetric cyclic ureas through a monoacylated diamine intermeidate | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-09-06 | — | — | US | disclosed |
| US-6218534-B1 | Preparation of asymmetric cyclic ureas through a monoacylated diamine intermediate | DUPONT PHARMACEUTICALS COMPANY | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112936-B2 | Five-membered heterocycles useful as serine protease inhibitors | F12, F11, F5 | GAA 2659/4885CYP3A4 742/4885PDPK1 2713/4885 |
| US-20180105509-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN7A, SCN1A, SCN1B | GAA 3148/4885CYP3A4 2632/4885PDPK1 1719/4885 |
| US-20010020093-A1 | Preparation of asymmetric cyclic ureas through a monoacylated diamine intermeidate | IMPDH1, IDE, DIMT1 | GAA 1170/4885CYP3A4 760/4885PDPK1 2255/4885 |
| US-20030175935-A1 | Method of identifying inhibitors of Lck | LCK, FYN, ZAP70 | GAA 1939/4885CYP3A4 4262/4885PDPK1 884/4885 |
| US-20180244626-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN1B, SCN1A, SCN3A | GAA 3772/4885CYP3A4 1566/4885PDPK1 575/4885 |
| US-10173985-B2 | Aminoindazole derivatives as sodium channel inhibitors | SCN1B, SCN1A, SCN3A | GAA 3892/4885CYP3A4 1429/4885PDPK1 592/4885 |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | F11, TFPI, F12 | GAA 3498/4885CYP3A4 692/4885PDPK1 3591/4885 |
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | MKI67, PCNA, MYC | GAA 952/4885CYP3A4 4298/4885PDPK1 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.